Pregnancy, Ovarian Clinical Trial
Official title:
Assessment of the Risk of Imprinting Defects in Children Born Following Assisted Reproductive Technologies (ART)
Genomic imprinting, referring to an epigenetic marking resulting in monoallelic gene expression, plays a critical role in development. Recently, various imprinting diseases were reported in animals (Large Offspring syndrome (LOS)) and humans (Beckwith-Wiedemann syndrome (BWS) and Angelman syndrome (AS)) born after ART. In all cases, an imprinting defect was involved (loss of methylation at ICR2 in BWS, at SNRPN in AS and at IGF2R DMR2 in LOS). These data suggest that ART procedures may impair the establishment or the maintenance (following fertilization) of methylation marks at maternally imprinted loci. In view of these data, the aim of this study is to determine if children born following ART exhibit an increased risk of imprinting defects. If the answer is yes, the second objective is to identify the problematic step in the ART procedure and thus to suppress or modify this step.
Methodology: assessment of the methylation status at 9 different imprinted loci (using
Southern blot and methyl-specific quantitative PCR) in 3 groups of patients: 150 children
naturally conceived, 150 children conceived after ovarian stimulation but with in vivo
fertilization, and 150 children conceived after ovarian stimulation and in VITRO
fertilization. These analyses will be performed on cord blood. Fragments of placental tissue
will also be collected for further analyses. Patients will be selected in maternity
hospitals associated with ART departments ( ANTOINE BECLERE HOSPITAL, Cochin HOSPITAL,
Saint-Vincent de Paul HOSPITAL, Jean VERDIER HOSPITAL, Tenon HOSPITAL and Dijon Hospital).
This work is also a unique opportunity to establish a DNA, RNA and tissue collection
allowing further investigation regarding other epigenetic modifications than DNA
methylation, not only at imprinted loci, but also in other genomic regions regulated by
epigenetic modifications.
;
Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03463278 -
The Number of Blastocysts Formed in the Outcome of Freeze All Strategy: COMFFETI Trial, Cumulative Delivery Rate
|
||
Completed |
NCT02442895 -
Biomarkers of Ovarian Reserve and Correlation With IVF Treatments
|
N/A | |
Recruiting |
NCT03693534 -
Clinical and Live Birth Rates After Following Long Antagonist Protocol Versus Long Agonist Protocol
|
||
Recruiting |
NCT03684421 -
Clinical and Live Birth Rates After Following Long Antagonist Protocol Versus Classical Antagonist Protocol
|
||
Recruiting |
NCT03240159 -
Long Antagonist Protocol for IVF With Single Luteal Dose of Degarelix
|
Phase 3 |